Pharmapack 2023 a Pivotal Moment for Sustainability in Drug Delivery and Packaging
Pharmapack Europe 2023 (February 1-2, 2023) closed earlier this month with the drug delivery and packaging community predicting sizeable growth through 2023 and sustainability dominating the at show agenda and innovations. The event, widely seen as a key bellwether for pharma packaging and delivery trends, marks a potential watershed moment for industry sustainability – with the topic dominating initiatives, trends and innovations thought-out the show.
Emphasising the renewed strength and growth in the industry, Pharmapack Europe 2023 played host to 4850 in person executives, spanning some 7513 visits, and 4210 online attendees. Remarkedly, at a time when some travel restrictions are still in place, 78 countries were represented and 42 content sessions held – with an entire track dedicated to Sustainability and two more covering Device & Packaging Innovation and Large Volume Drug Delivery & Combination Product. On demand content will remain available online for anyone that missed the sessions outlining industry prospects in 2023 and beyond.
Laura Indriksone, Brand Director at Pharmapack Europe commented: “We have seen a really big shift in 2023 and our own Pharmapack Report predicted sustainability will be the biggest single issue for the industry this year. What we saw on the show floor was the depth and diversity of response to meet the challenges of sustainable drug delivery innovation and greener packaging supply chains. The other major trend is that companies are trying to marry connected devices and sustainability goals and we also see many smaller companies at the event. I think this could be a big trend of the year ahead, that the industry is looking for new partners and is being much more open in its consideration criteria. Companies both big and small are looking to widen networks and make supply chains more diverse and more secure.”
In total, some 355 companies exhibited including a who’s who of packaging and delivery innovators from Aptar and BD to Nemera, Körber, West and Owen Mumford to name just a few. Indrikson added “if you look around and speak to people on the event floor, the single biggest comment is that the industry in incredibly excited and motivated to be back in person, meeting contacts, doing business and learning the key trends. Pharmapack is at the heart of pharma packaging and delivery.”
Speaking on the success of the event, and the breadth of trends and partnering, Julie Cotterell, Marketing Manager, Pharmaceutical Services, Owen Mumford, added: “The number of delegates was excellent with a return to the normal buzz of the show. From an Owen Mumford Pharmaceutical Services perspective, the quality of the partners in attendance was very strong and we had in-depth discussions with customers which bodes very well for industry growth in 2023. It was also interesting to see the shift in focus on presentations with sustainability definitely this year’s ‘hot topic’. In fact, our own expert Isobel Filipova delivered a session to a packed audience on ‘integrating product design in drug delivery for the circular economy’.”
Aptar Pharma again used the event to showcase some the sectors newest drug device breakthroughs, and Ciara Jackson, Senior Marketing Manager External Communications, predicted that this will be the year that shifts the sustainability agenda onto the pharma supply chain. She added, “it was another amazing event, with lots of novel collaborations being shaped that will improve outcomes in the next few years. Cutting-edge innovation, specifically around improved sustainability, is the key trend we saw for 2023. Anything that improves life-cycle impact for pharma from reduced API use in devices to our own APF Futurity – the first metal-free multidose nasal spray that can be recycled as one item. As an industry, I see 2023 as the year that pharma really zeros in on its supply chain partners and their impacts and contributions.”
Preparations for Pharmapack 2024 are already underway, with the event returning again to the Paris Expo, Porte de Versailles (24 & 25 January 2024).
- OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Read more
- Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer Read more
- BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Read more
- Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read more
- Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Read more